SCHEMBL5574387

SCHEMBL5574387

Cc1cccnc1CN(Cc1ncccc1C)C1CCN(c2[c]cccc2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 6/20 0.38
CHRM2 P08172 2/20 0.35
CHRM4 P08173 2/20 0.35
CHRM5 P08912 2/20 0.35
CHRM1 P11229 2/20 0.35
CHRM3 P20309 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
SLC6A2 P23975 2/20 0.34
SLC6A4 P31645 2/20 0.34
SLC6A3 Q01959 2/20 0.34
CCR5 P51681 2/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KCNH2 Q12809 1/20 0.32
EGLN1 Q9GZT9 2/20 0.31
GABRA1 P14867 1/20 0.31
GABRG2 P18507 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23428555 0.80 KDM4E (0.46) CXCR4CHRM2CHRM4CHRM5CHRM1
SCHEMBL23428766 0.78 CXCR4 (0.43) CXCR4CHRM2CHRM4CHRM5CHRM1
SCHEMBL2086062 0.77 CXCR4 (0.39) CXCR4CHRM2CHRM4CHRM5CHRM1
SCHEMBL2083565 0.76 CXCR4 (0.37) CXCR4CHRM2CHRM4CHRM5CHRM1
SCHEMBL2086381 0.76 CXCR4 (0.40) CXCR4CHRM2CHRM4CHRM5CHRM1
SCHEMBL2084679 0.75 L3MBTL1 (0.48) CYP2D6SLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL2081333 0.75 CXCR4 (0.40) CXCR4CHRM2CHRM4CHRM5CHRM1
SCHEMBL2084852 0.75 CXCR4 (0.42) CXCR4CCR5MEN1KMT2AKCNH2
SCHEMBL4535370 0.75 CCR5 (0.44) CXCR4CCR5MEN1KMT2AKCNH2
SCHEMBL5576989 0.75 CXCR4 (0.40) CXCR4CHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 US disclosed